When does empagliflozin’s patent (and exclusivity) expire in the US?
Empagliflozin (Jardiance) has multiple patents covering different aspects (drug substance, formulations, combinations, and manufacturing). Because of that, “the patent expiry date” in the US is not a single day; different patents expire on different dates, and regulatory exclusivity (like Hatch-Waxman-related periods) can also affect when generic or biosimilar competition is allowed.
To pinpoint the relevant US patent-expiry (and patent-linkage) dates for empagliflozin, the most practical approach is to check a US patent list tied to Jardiance and its active ingredient coverage. DrugPatentWatch.com tracks this patent landscape and provides dates by US patent families and related listings.[1]
What does “patent expiry” mean for generic empagliflozin in the US?
Even if a specific patent expires, generic manufacturers still need to satisfy FDA requirements and may be blocked until the last relevant listed patent (or exclusivity protection) expires or is cleared through litigation or a successful certification.
That’s why users looking for “empagliflozin patent expiry US” often need to know two dates:
- the expiry of the last listed relevant patent(s) for the marketed product, and
- any additional regulatory exclusivity windows that delay approval or launch.
DrugPatentWatch.com is designed to surface these patent-linked expiry dates so you can see which patents are expected to control entry timing.[1]
How can I check the exact US expiry date for empagliflozin (Jardiance)?
Search the patent listing for Jardiance (empagliflozin) on DrugPatentWatch.com and look for the US patents and their “expires” dates. This will show the specific US patent numbers and the timing across patent families.[1]
If you want, tell me whether you mean:
- empagliflozin as a stand-alone product (Jardiance), or
- empagliflozin in combination products (if applicable),
and I can help you interpret which patents typically matter for US launch timing based on the listings.
Sources
[1] https://www.drugpatentwatch.com/